Gliomatosis cerebri

Gliomatosis cerebri is a rare primary brain tumour, which according to WHO classification belongs to glial tumours of unknown origin. It is characterised by a diffuse infiltration of neoplastic-, astrocytic- and oligodendroglial cells into surrounding tissue. The diagnosis of Gliomatosis cerebri implies that at

least 3 lobes are affected.

Histology of Gliomatosis cerebri

  • often low malignancy of cells
  • because of the special growth pattern it is classified as WHO grade III


Epidemiology of Gliomatosis cerebri

  • usually in median and high adult age
  • can also occur in children


Symptoms of Gliomatosis cerebri

  • nonspecific, depending on localisation of tumour
  • headache and epileptic seizures
  • frequently mental changes (behaviour disorder or disturbance of memory)


Diagnosing Gliomatosis cerebri

  • with CT and/or MRI
  • rarely contrast agent enhancement
  • diagnostic confirmation with biopsy
  • specific, extensive infiltration of brain tissue
  • in at least three lobes
  • can affect entire CNS


Therapy of Gliomatosis cerebri

  • no established standard therapy because of tumours rarity
  • in individual cases in asymptomatic patients with confirmed diagnosis the tumour can be oberserved for a certain time
  • in case of relevant symptoms or significant tumour growth treatment is necessary
  • chemotherapy (e.g. PCV scheme or temozolomide)
  • stereotactic radiotherapy or whole brain radiation therapy


Course of Gliomatosis cerebri

  • growth depends on WHO grade


Prognosis of Gliomatosis cerebri

  • depending on patient´s condition, histology and WHO grade
  • if radio- and chemotherapy improve prognosis has not been investigated prospectively
  • there are indications for the effectiveness of both therapies

Latest News

NOA-Jahrestagung II

Update zu laufenden und geplanten NOA-Studien und Zukunftsvisionen

 > more

NOA-Jahrestagung I

Neues von der WHO-Klassifikation der Hirntumoren

 > more

Individualisierte Therapie

NOA-20-Studie untersucht Therapiewahl auf Basis molekularer Marker

 > more